Nuformix plc (LON:NFX – Get Free Report) was down 12.5% during mid-day trading on Monday . The company traded as low as GBX 0.14 ($0.00) and last traded at GBX 0.14 ($0.00). Approximately 621,549 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 3,147,163 shares. The stock had previously closed at GBX 0.16 ($0.00).
Nuformix Stock Performance
The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The company has a market capitalization of £1.15 million, a P/E ratio of -1.63 and a beta of 1.22. The business’s fifty day simple moving average is GBX 0.17 and its 200-day simple moving average is GBX 0.19.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- What is a Special Dividend?
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Bank Stocks – Best Bank Stocks to Invest In
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What Makes a Stock a Good Dividend Stock?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.